FNO watchlist for Tomorrow 👇 #LALPATHLAB #ZEEL #CONCOR #FSL #ASTRAL

Lalpathlab 2270 And Dip 2250 to 2370 100 point in one session #TradeAdda #LALPATHLAB

Result today: #BAJAJFINSV #DRREDDY #NESTLEIND #INTELLECT #LALPATHLAB

WEEKLY MARKET REPORT :- #NIFTY50 #TANLA #TCS #LALPATHLAB Indian equity benchmark indices settled 1 percent lower for the week ended July 15 amid volatility, weak GDP data and rising global inflation, which fueled the fears of a further rate hike by central banks across the world. However, reduced FIIs selling, lower crude oil prices and a good monsoon provided some support to the market. During the week, BSE Sensex lost 721.06 points (1.32 percent) to settle at 53,760.78, while the Nifty50 declined 171.4 points (1.05 percent) to end at 16,049.20 levels. However in the month of July, till now, the benchmark indices have gained over 1 percent each. On the sectoral front, BSE Power index added 4.5 percent and BSE Oil & Gas, Auto and Realty indices rose 2 percent each. However, Information Technology index shed 6 percent. Among broader indices - BSE Small-cap index rose 0.5 percent, Mid-cap added 1 percent, while Large-cap index shed 0.5 percent. “After an extremely volatile week, the equity market witnessed some recovery at the weekly closing probably due to some amount of short covering ahead of the weekend. There have been some signs of improvement in the overall macro environment mainly due to the surge in the US Dollar and the consequent fall in commodity prices especially Brent,” said Joseph Thomas, Head of Research, Emkay Wealth Management. “But currency depreciation might eat into some of the gains made in prices after the fall, as trade deficit moves close to USD 196 billion. The US inflation number surged past the 9% level and was much higher than general expectations, and this fuelled the speculation on the quantum of the next rate hike by the Fed. The market will be looking forward to the FOMC meeting as also other related developments to gauge the direction better,” he added. In the last week, foreign institutional investors (FIIs) offloaded equities worth of Rs 5,916.01 crore. However, domestic institutional investors (DIIs) purchased equities worth of Rs 2,146 crore. However, in the month of July, FIIs sold equities worth Rs 10,459.13 crore and DIIs bought equities worth of Rs 7,367.04, till now. In last week, 40 smallcap stocks rose between 10-52 percent including PC Jeweller, ITI, Butterfly Gandhimathi Appliances, Mahanagar Telephone Nigam, Parag Milk Foods, GTL Infrastructure, Precision Camshafts, Anupam Rasayan India and Garware Hi-Tech Films. On the other hand, KBC Global, DB Realty, Kriti Industries (India), Shakti Pumps (India), Tanla Platforms and Axtel Industries lost over 10 percent each. “Sensex and Nifty saw some profit booking this week; however, broader indices ended this week with marginal gains. Sectorally, the performance was mixed, with BSE Power index posting strong gains. On the other hand, BSE IT reported sharp decline this week. Q1FY23 results of large IT companies were weaker than expected,” said Shrikant Chouhan, Head of Equity Research (Retail) at Kotak Securities. “Recent high inflation numbers and recession fear in US coupled with sharp rally in dollar index influenced global markets. India's headline CPI inflation in June was flattish month-on-month.” Markets will continue to react to global macro factors like inflation, interest rate measures, currency and commodity movement, Chouhan said adding that with the start of April-June 2022 quarter result season, we can expect stock and sector specific action over the next one month. Among midcaps, gainers were IDBI Bank, JSW Energy, PI Industries, Crompton Greaves Consumer Electrical, NHPC, SJVN, Oberoi Realty, Adani Power and Bharat Heavy Electricals. However, Losers included REC, Endurance Technologies, AU Small Finance Bank, Info Edge India and MphasiS. Among BSE 500 index ended on flat note. Gainers included ITI, Anupam Rasayan India, HFCL, Star Health & Allied Insurance Company, KEC International, Aster DM Healthcare, Vakrangee and Adani Transmission. However, losers were Tanla Platforms, HCL Technologies, Birlasoft, Dr Lal PathLabs, Tata Consultancy Services, Mastek and NMDC. “We witnessed some correction in Nifty during the week but the index has not breached its important support levels. It has retraced recent upmove from 15180 to 16270 by 38.2 percent and the rising trendline support around 15800 has also not been breached,” said Ruchit Jain, Lead Research, 5paisa.com. On the lower time frame chart, a ‘Higher Top Higher Bottom' structure is seen which is still valid and until the index breaks the important support of 15800, the near term outlook remains bullish, according to Jain. “The Bank Nifty index showed relative underperformance on Friday, but this index too has a similar positive structure and the 20-day moving average support for the same is placed around 34360,” Jain explained. “The Midcap space outperformed the benchmark and ended the week with gains of a percent. This clearly indicates a buying interest in the broader markets and hence, stock specific action is likely to continue with a positive bias,” he added. Where is Nifty50 headed? Sameet Chavan, Chief Analyst-Technical and Derivatives, Angel One The global environment is still not conducive, but our markets are not willing to give up as they continue to attract some buyers at lower levels. Technically speaking, 15850 – 15950 has now become a sacrosanct zone for the forthcoming week and if global markets support, we may see markets inching northwards. Hence, one should continue to remain positive till the time we do not sneak below it on a sustainable basis. On the flip side, there are a lot of headwinds that are not willing markets to stay at higher levels. For the coming week, 16150 – 16250 are to be seen as immediate resistances and only a move beyond this would trigger some broad-based buying in the market. At this juncture, it's advisable to stay light and identify the apt themes that remain a key for momentum traders. Amol Athawale, Deputy Vice President - Technical Research, Kotak Securities Markets may remain volatile on worries of further rate hikes by the US Fed and unabated FPI outflows. Technically, on weekly charts the Nifty has formed an inside body Hammer kind of formation which indicates indecisiveness between the bulls and bears. For the bulls, the 50-day SMA (Simple Moving Average) and 16000 would act as a trend decider level. A strong possibility of a fresh uptrend rally is likely, if the index trades above 16000-16050, which is a short term resistance zone. Above the same, the index could rally till 16200-16300. On the flip side, a close below 50-day SMA or 15850 could trigger a fresh round of selling. Below which the index could slip till 15700-15650. Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions. CREDIT : MONEYCONTROL BLOG

This view is based on volume, oi, delivery data & price action. ALL Posts are for educational purposes only & not any recommendation POSSIBLE BEARISH FOR COMING DAYS-> #ABBOTINDIA #HAVELLS #IGL #LALPATHLAB #LTI #LTTS #MARICO #NAUKRI #PERSISTENT #STAR

#LALPATHLAB 3800CE buy abv 234 tar 260 275 sl 208

#LALPATHLAB 3898 : Target 4070 & more in Positional Trades (Swing,Momentum,Trending,Invest) channel on FrontPage

EQUITY WATCHLIST TODAY #AUROPHARMA #SBILIFE #PIDILITIND #HDFCAMC #LALPATHLAB

EQUITY WATCHLIST TODAY #TRENT #BRITANNIA #ICICIBANK #LALPATHLAB #TATACHEM

https://youtu.be/pSbaj4OMpTI Analysis, Prediction & Levels for 02.09.2021 #NIFTY50 #NIFTYBANK #LALPATHLAB #CANBK #BHEL

Looking good for BTST/For coming days... (Strictly cash) #BHEL #VOLTAS #TATAMOTORS #HINDPETRO #LALPATHLAB BTST involves risk of Gap Downs because of Global cues. Consider that before entering.

One can book partial profits here #LALPATHLAB

#LALPATHLAB buy at cmp 3940 options 3950CE

Prabhudas Lilladher target on LALPATHLAB Date: 03-Aug-21 Broker: Prabhudas Lilladher Price @ Call: 3883.1 Target: 2626 Potential: -32.37% Recommendation: SELL

#LALPATHLAB 2700 to 3200 ,3350 then

#DIXON and #RELAXO for the coming weeks would be a safe. Call options of #LALPATHLAB would be something to look at but the train seems to have already left the station. #RELIANCE could be added if we get a deep pullback and chemicals and tech sector would be ones to watch out for. If the price is right #TECHM could be added for a positional as it is at a decent price. A few solid points there could also give enough for the week.

#LALPATHLAB Q4 PAT jumps 161% YoY Revenue rose 42.9% year-on-year (YoY) to Rs 431 crore during the quarter. The company's non-COVID business grew at a growth rate of 26.8% YoY in Q4 FY21. COVID portfolio contribution to total revenue declined to 11.2% in Q4 FY21 from 21.6% in Q3 FY21 due to regulations on pricing of RTPCR testing. COVID allied business in Q4 FY21 was at 12.5% of total COVID portfolio. The company conducted 4.5 lakh COVID RTPCR tests conducted in Q4 FY21, with RT-PCR test being conducted in 14 labs across the country. Normalised EBITDA (after adjustment for stock-based compensation & CSR cost) for Q4 FY21 was at Rs 129.5 crore, up by 101.7% from Rs 64.2 crore in the same quarter last year. Normalised EBITDA margin was at 30% as on 31 March 2021 as against 21.3% as on 31 March 2020. Profit before tax in the fourth quarter stood at Rs 110.8 crore, up by 144.1% from Rs 45.4 crore in the same period last year. The diagnostic services provider reported 30.3% jump in consolidated net profit to Rs 296.5 crore on 18.9% rise in revenue to Rs 1,581.3 crore in the year ended 31 March 2021 over the year ended 31 March 2020. Cash, FDs and mutual funds were at Rs 985.9 crore as on 31 March 2021, an increase of Rs 241.7 crore over 31 March 2020. The board approved a final dividend of Rs 8 per equity share. Commenting on the results announcement, (Hony) Brig. Dr. Arvind Lal, executive chairman, said: "Even though the concluding quarter of FY21 was marked by the second wave of COVID-19 pandemic in India, we have ensured that our non-COVID business has shown growth. The COVID business started increasing by the end of the quarter due to the growing caseload of COVID cases. In our bid to sustain the market leadership position, we continue to expand test menu, penetrate into newer geographies and strengthen our hold in existing regions." Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services. As on 31 March 2021 the company has 231 clinical laboratories, 3,705 patient service centers (PSCs) and 9,247 pickup points (PUPs). The scrip shed 0.73% to end at Rs 2833.65 on Friday.

🔥 *MULTIBAGGER SHARE OF 2021*🔥 🚀 *"LALPATHLAB"*🚀 *💰CMP 2855* *TG 2950/3000/3500/4000/5000+++💰* *(PLACE BUY BID TOMORROW AT PRE OPEN 9AM WITH LIMIT PRICE OF MAXIMUM 2880 IF YOU WANT TO BUY IT EARLY BEFORE ITS OPENING PRICE)* 📈 *READ SOME INFORMATION ON IT WHY WE ARE SO BULLISH ON IT* 👇🏻 😎 *BIG NEWS OF Q4 RESULTS*👇🏻 *1) TOMORROW COMPANY GOING TO POST ITS Q4 RESULTS* *ESTIMATES FROM Q4*👇🏻 *🔥) PROFIT CAN JUMP 300% THIS TIME* *🔥) PROFIT CAN JUMP TO 125CR VS 32 CR ( LAST YEAR)* *🔥) MARGINS CAN JUMP TO 33% VS 19%( LAST YEAR)* 👇🏻 *TECHNICAL VIEW* 👇🏻 *1) LALPATHLAB AFTER GOING TO THE LEVELS OF 3400 LEVELS SHOWN A HEALTHY CORRECTION AND NOW RETESTED ITS EARLIER BREAKOUT OF 2800* *2) SUCCESSFULLY CLOSED ABOVE THE MAJOR SUPPORT OF 2800-2850* *3) TOMMROW IF IT BREAKS 2890 IT CAN GO TO 2950-3000 TOMMROW ONLY* *👇🏻FUNDAMENTAL VIEW*👇🏻 *1) LALPATHLAB IS THE BIGGEST PLAYER OF ITS INDUSTRY* *2) HAVING A MARKET CAP OF 24000 CR* *3) ZERO DEBT COMPANY* *4) STRONG PROMOTER , FII , DII AND MUTUAL FUNDS HOLDING OF 93%* 🔥 *5) COVID HAS CAME AS A BOON TO THIS SECTOR GOING TO INCREASE ITS PROFIT MULTIFOLD* *BUY LALPATHLAB FOR - INTRADAY / SHORT TERM / LONG TERM* *(ALL IN ONE )🔥 HOT STOCK FOR TOMMROW* #LALPATHLAB

Health care stock on fire post RBI announcement of INR 50000 cr term liquidity facility for the sector - entities including vaccine manufactures; importers/suppliers of vaccines -priority medical devices; hospitals/dispensaries; pathology labs; manufactures and suppliers of oxygen and ventilators; importers of vaccines and COVID related drugs; logistics firms and also patients for treatment. #DRREDDY #CADILAHC #APOLLOHOSP #THYROCARE #LALPATHLAB

CARRIED:: SELL LALPATHLAB APR BELOW 2815 #LALPATHLAB

**BUY LALPATH LAB ABOVE 2340** **TG 2350/2360/2380/2400** **SL 2328** #LALPATHLAB

*TATA MOTORS 3Q NET INCOME 29.1B RUPEES; JLR PRETAX GBP439M* *TATA MOTORS 3Q REV. 756.5B RUPEES, +5.5% Y/Y; EST 766.59B *TATA MOTORS 3Q JLR REV. GBP5.98B *TATA MOTORS 3Q JLR EBITDA MARGIN 15.8%* *TATA MOTORS 3Q TOTAL COSTS 717.8B RUPEES, +0.8% Y/Y *TATA MOTORS 3Q FINANCE COST 21.3B RUPEES, +22% Y/Y *TATA MOTORS CONFIDENT OF ACHIEVING TARGETED SAVINGS OF INR60B *VEDANTA 3Q NET INCOME 33B RUPEES, EST. 26.63B *VEDANTA 3Q REV. 225B RUPEES, EST. 225.33B *VEDANTA 3Q FINANCE COST 13.2B RUPEES, +7.3% Y/Y *VEDANTA 3Q TOTAL COSTS 182.1B RUPEES, -0.9% Y/Y *UPL 3Q NET INCOME 7.94B RUPEES, EST. 8.96B *UPL 3Q REV. 91.3B RUPEES, EST. 97.14B *UPL 3Q EBITDA 22.1B RUPEES, EST. 22.97B* *UPL 3Q OTHER INCOME 670M RUPEES *UPL MAINTAINS GUIDANCE OF 6-8% GROWTH IN REVENUE *UPL MAINTAINS GUIDANCE OF 10-12% GROWTH IN EBITDA *LAL PATHLABS 3Q NET INCOME 945M RUPEES, EST. 738.3M *LAL PATHLABS 3Q REV. 4.52B RUPEES, EST. 4.02B *LAL PATHLABS 3Q TOTAL COSTS 3.37B RUPEES, +26% Y/Y *DISH TV INDIA 3Q NET INCOME 906.9M RUPEES *DISH TV INDIA 3Q REV. 8.16B RUPEES, -6% Y/Y *DISH TV: APPROVES DIVESTMENT OF ENTIRE EQUITY IN DISH TV LANKA* #TATAMOTORS #VEDL #UPL #LALPATHLAB #DISHTV

#InvestmentIdeas #LALPATHLAB Lal path Labs CMP 2409 Lal path labs operates its own path labs, while collection centres are primarily run on a franchisee model. Though operations are spread across the country, northern India accounts for over 70% of total revenue. Financial - ROE and ROCE is around 22% and 32% respectively (Positive) - Face Value - INR 10, P/BV - 17 - Debt free company - Forward PE - 65 (Average as per Industry benchmark. - Promoter holding is around 55.2% which is decreased by more than 1% in Q2FY21 however FIIs incresed their stake from 20% to 22.4%, DIIs hold around 9.6% which is also decreased by more than 1% - Operating profit margin is around 28-30%, impacted in Q4FY20 and Q1FY21 due to lockdown impact. - Q2FY21 topline was around INR 432 Crs Vs. 366 Crs therefore up by 18% YoY. - Q2FY21 operating profit was around INR 315 Crs Vs. 238 Crs therefore up by 32% in YoY. - Strong operating cash flows in every quarter. Sound liquidity in the system as debtor realization period is too good. Key positive / strength - Leading market position backed by established brand and strong infrastructure network. Pan-India network of 216 clinical laboratories, 3095 patient service centres, and 6995 pick-up points. - Strong liquidity, networth around INR 932 Cr as of March 2020, driven by healthy cash reserves of Rs 731 crore (Rs 1-2 crore are lien marked against bank guarantees) as on Sep 30, 2020 in form of cash and fixed deposits balance in bank and also market instruments like mutual funds. - Tie up with various hospital networks for some of the diagnostic test. Risk/Weakness - Intense competition in the diagnostic services market, which has several large and small players offering similar services, results in pricing pressure. Strong brand reputation and experience more than 50 years in diagnostic field still sluggish topline growth. View Share has given strong return after IPO debut in 2016 and it's almost 3x. The good thing about diagnostic chain is leading to increase health care budget, corporate tie ups, new diseases and post Covid ample opportunities and growth. Share has already given breakout above 2350 level and sustained it also. Look like good for short to mid term for 2600/2700. Stronf support at 2250/2180.

#InvestmentIdeas #LALPATHLAB Lal path Labs CMP 2409 Lal path labs operates its own path labs, while collection centres are primarily run on a franchisee model. Though operations are spread across the country, northern India accounts for over 70% of total revenue. Financial - ROE and ROCE is around 22% and 32% respectively (Positive) - Face Value - INR 10, P/BV - 17 - Debt free company - Forward PE - 65 (Average as per Industry benchmark. - Operating profit margin is around 28-30%, impacted in Q4FY20 and Q1FY21 due to lockdown impact. - Q2FY21 topline was around INR 432 Crs Vs. 366 Crs therefore up by 18% YoY. - Q2FY21 operating profit was around INR 315 Crs Vs. 238 Crs therefore up by 32% in YoY. - Strong operating cash flows in every quarter. Sound liquidity in the system as debtor realization period is too good. Key positive / strength - Leading market position backed by established brand and strong infrastructure network. Pan-India network of 216 clinical laboratories, 3095 patient service centres, and 6995 pick-up points. - Strong liquidity, networth around INR 932 Cr as of March 2020, driven by healthy cash reserves of Rs 731 crore (Rs 1-2 crore are lien marked against bank guarantees) as on Sep 30, 2020 in form of cash and fixed deposits balance in bank and also market instruments like mutual funds. - Tie up with various hospital networks for some of the diagnostic test. Risk/Weakness - Intense competition in the diagnostic services market, which has several large and small players offering similar services, results in pricing pressure. Strong brand reputation and experience more than 50 years in diagnostic field still sluggish topline growth. View Share has given strong return after IPO debut in 2016 and it's almost 3x. The good thing about diagnostic chain is leading to increase health care budget, corporate tie ups, new diseases and post Covid ample opportunities and growth. Share has already given breakout above 2350 level and sustained it also. Look like good for short to mid term for 2600/2700. Stronf support at 2250/2180.

Results Today #ITC #CIPLA #LALPATHLAB #CREDITACC #BALKRISIND

Expects Diagnostic stocks will be positive after Thyrocare Technologies announced strong earning guidance. Stock gained nearly 30% in the last two trading sessions after the announcment. Company says that it has conducted more than 4 lakh Covid-19 RT-PCR tests and more than 3.2 lakh Covid-19 antibody tests as on September 30. Have enhanced capacity to do RT-PCR tests up to 400 per hour. Revenue for the quarter up 37% as compared to last year and up 171% as compared to the previous quarter. Expects positive for other Diagnostic stocks like Dr Lal Pathlab, Metropolis and Apollo Hospital #LALPATHLAB #APOLLOHOSP #METROPOLIS #THYROCARE

*Result Highlight* Glaxosmithkline Pharmaceuticals Ltd. Q4 Cons: Net profit down -6% at Rs. 138.07 cr. Vs Rs. 146.81 cr. (YoY) and Revenue up 3.3% at Rs. 775.8 cr. Vs Rs. 750.81 cr. (YoY) Board of Directors recommend a Dividend of Rs 40 per equity share of face value of Rs.10 each which includes a special dividend of Rs. 20 per share for this year. (Year ended 31st March 2019 Rs.20 per share). Torrent Power Ltd. Q4 Cons: Net loss at Rs. -274.92 cr. (due to an exceptional item, company made a provision of Rs 1,000 crore as exceptional item in the quarter towards carrying cost of DGEN plant Dahej, Gujarat) Vs profit of Rs. 23.95 cr. (YoY) and Revenue up 2% at Rs. 2983.5 cr. Vs Rs. 2924.8 cr. (YoY) Astrazeneca Pharma India Ltd. Q4: Net profit down -2.5% at Rs. 9.57 cr. Vs Rs. 9.82 cr. (YoY) and Revenue up 2.4% at Rs. 194.9 cr. Vs Rs. 190.3 cr. (YoY) Dr. Lal PathLabs Ltd Q4 Cons: Revenue was flat yoy however declined 8% qoq at Rs 301.7 cr impacted covid-19 lockdown as volumes were lower. Net profit declined 31% yoy & 41% qoq at Rs 32.6 cr. Delta Corp Ltd. Q4 Cons: Net profit down -48.8% at Rs. 29.04 cr. Vs Rs. 56.72 cr. (YoY) and Revenue down -11.4% at Rs. 180.93 cr. Vs Rs. 204.29 cr. (YoY) Monnet Ispat & Energy Ltd. Q4 Cons: Net loss of Rs. -121.23 cr. Vs loss of Rs. -171.19 cr. (YoY) and Revenue up 15.9% at Rs. 617.31 cr. Vs Rs. 532.82 cr. (YoY) Gujarat Themis Biosyn Ltd. Q4 : Net profit at Rs. 10.95 cr. Vs Rs. 2.51 cr. (YoY) and Revenue at Rs. 26.35 cr. Vs Rs. 10.35 cr. (YoY) Board of Directors of the Company has recommended a dividend of Rs. 1.65 per share Maharashtra Scooters Ltd. Q4 : Net profit at Rs. 107.14 cr. Vs Rs. 6.8 cr. (YoY) and Revenue at Rs. 6.35 cr. Vs Rs. 3.4 cr. (YoY) #TORNTPOWER #GLAXO #LALPATHLAB #ASTRAZEN